Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin)
- PMID: 3123239
- DOI: 10.1007/BF02467352
Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin)
Abstract
One boy and 13 girls with central precocious puberty were treated for 1 year using Buserelin, a GnRH analogue, given intranasally (0.3 mg, four times a day). After 1, 3 and 12 months of therapy, the gonadotropin responses to GnRH were abolished in all the patients whereas mean basal serum concentrations of luteinizing hormone (LH) remained similar to those of pubertal controls. During Buserelin treatment, genital development in the boy and breast development in the girls showed no further progress or some regression. In the boy, serum testosterone levels returned to prepubertal values. In the girls, serum oestradiol levels were variable and, in four of them, vaginal smears showed the persistence of a slight oestrogenic effect during therapy. Pelvic ultrasonography did not show any significant variation in ovarian and uterine lengths. Among the 14 patients, 3 had some progression of pubic hair development, irrespective of serum dehydroepiandrosterone sulphate (DHEAS) levels. In eight patients previously treated with cyproterone, elevated prolactin levels were observed before and during the first month of Buserelin administration. During treatment, mean height velocity was markedly reduced from 11.6 to 6.1 cm/year and mean bone age velocity (+/- 1SD) was 0.85 +/- 0.38 year/year. After 1 year of treatment, the differences in predicted adult height ranged between -0.74 and + 1.04 SDS (standard deviation score). These differences were inversely related (r = -0.72) to the prognosis of adult height calculated before treatment. We conclude that, in central precocious puberty, intranasal administration of Buserelin 1.2 mg/day, may arrest sexual development and reduce height velocity and bone maturation. Improvement of adult height prognosis may occur, especially when it was markedly impaired before treatment.
Similar articles
-
Central precocious puberty: current treatment options.Paediatr Drugs. 2004;6(4):211-31. doi: 10.2165/00148581-200406040-00002. Paediatr Drugs. 2004. PMID: 15339200 Review.
-
Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin.Acta Endocrinol (Copenh). 1987 Dec;116(4):519-25. doi: 10.1530/acta.0.1160519. Acta Endocrinol (Copenh). 1987. PMID: 3122484
-
Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.Horm Res. 1993;39(3-4):111-7. doi: 10.1159/000182709. Horm Res. 1993. PMID: 8262471
-
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).J Clin Endocrinol Metab. 1995 Oct;80(10):3059-67. doi: 10.1210/jcem.80.10.7559897. J Clin Endocrinol Metab. 1995. PMID: 7559897 Clinical Trial.
-
Disorders of Puberty: An Approach to Diagnosis and Management.Am Fam Physician. 2017 Nov 1;96(9):590-599. Am Fam Physician. 2017. PMID: 29094880 Review.
Cited by
-
Central precocious puberty: current treatment options.Paediatr Drugs. 2004;6(4):211-31. doi: 10.2165/00148581-200406040-00002. Paediatr Drugs. 2004. PMID: 15339200 Review.
-
Hypothalamo-pituitary dysfunction in congenital toxoplasmosis.Eur J Pediatr. 1989 Aug;148(8):742-4. doi: 10.1007/BF00443099. Eur J Pediatr. 1989. PMID: 2792124
-
Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.Arch Dis Child. 1996 Oct;75(4):292-7. doi: 10.1136/adc.75.4.292. Arch Dis Child. 1996. PMID: 8984913 Free PMC article.
-
Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.Eur J Pediatr. 1990 Feb;149(5):308-13. doi: 10.1007/BF02171554. Eur J Pediatr. 1990. PMID: 2138079
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources